Biodesix (BDSX) Expected to Post Earnings on Wednesday

Biodesix (NASDAQ:BDSX) is anticipated to announce its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.86) per share and revenue of $26.0260 million for the quarter. Parties are encouraged to explore the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Biodesix (NASDAQ:BDSX) last released its earnings results on Monday, May 4th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.32. Biodesix had a negative net margin of 33.26% and a negative return on equity of 2,101.40%. The firm had revenue of $25.55 million during the quarter, compared to the consensus estimate of $23.12 million. On average, analysts expect Biodesix to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Biodesix Trading Up 3.9%

Shares of BDSX stock opened at $22.03 on Tuesday. The company has a quick ratio of 2.82, a current ratio of 2.82 and a debt-to-equity ratio of 5.09. The firm has a market cap of $228.23 million, a P/E ratio of -5.43 and a beta of 0.56. The company has a 50 day moving average of $19.07 and a 200-day moving average of $15.34. Biodesix has a 12-month low of $5.26 and a 12-month high of $24.92.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. HC Wainwright assumed coverage on Biodesix in a report on Monday, June 15th. They set a “buy” rating and a $26.00 price objective for the company. Weiss Ratings upgraded Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 12th. Canaccord Genuity Group boosted their target price on Biodesix from $22.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. Finally, Roth Capital initiated coverage on Biodesix in a research report on Wednesday, June 24th. They set a “buy” rating and a $32.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $28.33.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. XTX Topco Ltd grew its stake in Biodesix by 99.4% during the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after acquiring an additional 102,494 shares in the last quarter. Trexquant Investment LP purchased a new stake in Biodesix in the 4th quarter worth approximately $187,000. DRW Securities LLC purchased a new stake in Biodesix in the 4th quarter worth approximately $105,000. Millennium Management LLC bought a new position in Biodesix in the 3rd quarter valued at $113,000. Finally, Cetera Investment Advisers bought a new position in Biodesix in the 4th quarter valued at $68,000. 20.96% of the stock is owned by institutional investors.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.